Clinical Trials Arena reports that Spinogenix expanded CLARITY, its ongoing Phase IIb/III basket trial. The addition is a Phase IIb study evaluating codabakalner in idiopathic ASD.
Why it matters: The expansion adds an idiopathic ASD study to the clinical research work covered by CLARITY.
Trial conduct and operationsAI summary
Read at Clinical Trials Arena